As of 2025-05-12, the EV/EBITDA ratio of Karyopharm Therapeutics Inc (KPTI) is -2.76. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KPTI's latest enterprise value is 249.90 mil USD. KPTI's TTM EBITDA according to its financial statements is -90.70 mil USD. Dividing these 2 quantities gives us the above KPTI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.3x - 10.4x | 7.5x |
| Forward P/E multiples | 10.5x - 15.8x | 11.4x |
| Fair Price | (134.28) - (133.01) | (123.17) |
| Upside | -2334.3% - -2313.2% | -2149.4% |
| Date | EV/EBITDA |
| 2025-05-09 | -2.76 |
| 2025-05-08 | -2.77 |
| 2025-05-07 | -2.76 |
| 2025-05-06 | -2.78 |
| 2025-05-05 | -2.86 |
| 2025-05-02 | -2.88 |
| 2025-05-01 | -2.83 |
| 2025-04-30 | -2.83 |
| 2025-04-29 | -2.79 |
| 2025-04-28 | -2.76 |
| 2025-04-25 | -2.72 |
| 2025-04-24 | -2.75 |
| 2025-04-23 | -2.78 |
| 2025-04-22 | -2.76 |
| 2025-04-21 | -2.70 |
| 2025-04-17 | -2.65 |
| 2025-04-16 | -2.60 |
| 2025-04-15 | -2.59 |
| 2025-04-14 | -2.59 |
| 2025-04-11 | -2.59 |
| 2025-04-10 | -2.56 |
| 2025-04-09 | -2.59 |
| 2025-04-08 | -2.56 |
| 2025-04-07 | -2.57 |
| 2025-04-04 | -2.55 |
| 2025-04-03 | -2.55 |
| 2025-04-02 | -2.57 |
| 2025-04-01 | -2.52 |
| 2025-03-31 | -2.54 |
| 2025-03-28 | -2.58 |
| 2025-03-27 | -2.60 |
| 2025-03-26 | -2.65 |
| 2025-03-25 | -2.72 |
| 2025-03-24 | -2.80 |
| 2025-03-21 | -2.79 |
| 2025-03-20 | -2.77 |
| 2025-03-19 | -2.74 |
| 2025-03-18 | -2.74 |
| 2025-03-17 | -2.77 |
| 2025-03-14 | -2.83 |
| 2025-03-13 | -2.84 |
| 2025-03-12 | -2.90 |
| 2025-03-11 | -2.89 |
| 2025-03-10 | -2.91 |
| 2025-03-07 | -2.84 |
| 2025-03-06 | -2.77 |
| 2025-03-05 | -2.77 |
| 2025-03-04 | -2.79 |
| 2025-03-03 | -2.87 |
| 2025-02-28 | -2.94 |